Clinical Trials on Risk Factors in Belgium

Total 52 results

Universitaire Ziekenhuizen KU Leuven

Completed

Augmented Renal Clearance in the Adult Non-critically Ill Surgery Patient: a Prospective Point Prevalance Study (ARCPPS)

Prevalence of Augmented Renal Clearance | Risk Factors for Augmented Renal Clearance

Belgium
University of Oxford
British Heart Foundation; European Commission; Oxford University Hospitals NHS... and other collaborators

Recruiting

The Oxford Risk Factors And Non-Invasive Imaging Study (ORFAN)

Cardiovascular Diseases | Cardiovascular Risk Factors

United Kingdom, Germany, Belgium, China, United States, Australia, France, Greece, Hungary, Italy, Japan, Korea, Republic of, Netherlands, Romania, United Arab Emirates
Université Libre de Bruxelles

Completed

Comparison of Electronic Cigarettes and Tobacco Cigarettes on Cardiovascular Function and Oxidative Stress

Cardiovascular Risk Factor

Belgium
University Ghent

Completed

Relationship Between Footwear Consumer Behaviour and Lower Extremity Injuries

Sports Injury | Risk Factor | Footwear

Belgium
Universitair Ziekenhuis Brussel

Active, not recruiting

Low Grade Inflammation in Childhood Obesity : an Independent Risk Factor for Endothelial Dysfunction

Inflammation | Obesity | Endothelial Dysfunction | Obesity, Childhood | Cardiovascular Risk Factor

Belgium
Hasselt University

Unknown

Chronotropic Incompetence During Exercise Testing in Obese Adolescents

Obesity, Childhood | Cardiovascular Risk Factor | Cardiac Disease

Belgium
Erasme University Hospital

Terminated

Minimally Invasive Detection of a Sleep Apnoea (KCG_SLEEP)

Cardiovascular Diseases | Cardiovascular Risk Factor | Sleep Disorder; Breathing-Related | Cardiovascular Complication

Belgium
Universitair Ziekenhuis Brussel
Vrije Universiteit Brussel

Completed

Risk Analysis Interview IVDR 2023 (RAI-IVDR23)

Risk Variables

Belgium
Eindhoven University of Technology

Completed

Evaluation of the Impact of Adaptive Goal Setting on Engagement Levels of Government Staff With a Gamified mHealth Tool (BSAK19)

Lifestyle | Lifestyle, Healthy | Lifestyle Risk Reduction | Lifestyle, Sedentary

Belgium
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
Vrije Universiteit Brussel

Unknown

The Effect of a Physical Activity Program on Burnout Risk Among Secondary School Teachers

Physical Activity | Burnout Risk

Belgium
Université Catholique de Louvain

Completed

Hyperglycaemia In Childhood Hematologic Malignancies (DIAB-ONCO)

Diabetes Mellitus Risk

Belgium
Université Catholique de Louvain

Completed

Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation. (DIAB-GRAFT)

Diabetes Mellitus Risk

Belgium
Erasme University Hospital

Completed

Optimized Anesthesia to Reduce Postoperative Cognitive Impairment in the Elderly

Elderly ; Moderate Risk Surgery

Belgium
AstraZeneca

Completed

European Study of Cardiovascular Risk (EURIKA)

Smoking | Hypertension | Obesity | Diabetes | Hyperlipidemia | Cardiovascular Risk Factors

Sweden, France, Russian Federation, Spain, Turkey, United Kingdom, Germany, Norway, Austria, Belgium, Switzerland, Greece
Cliniques universitaires Saint-Luc- Université...

Completed

Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery (HNSCC)

Surgery | Head and Neck Squamous Cell Carcinoma | Growth Factor

Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib (LAT-FLOSI)

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Belgium
Janssen Research & Development, LLC

Completed

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Urothelial Cancer | Receptors, Fibroblast Growth Factor

United States, Italy, Belgium, United Kingdom, Japan, Turkey, Brazil, Ukraine, Spain, Russian Federation, Israel, France, Germany, Argentina
KU Leuven

Unknown

International Lung UltraSound Analysis (ILUSA) Study (ILUSA)

Pneumonia, Viral | Pneumonia | Pregnancy Related | Pregnancy, High Risk | COVID | Diagnoses Disease | Pregnancy Complications, Infectious | Pregnancy Disease

Belgium, Italy, United Kingdom
Université Libre de Bruxelles

Unknown

Ultrasound-guided Lumbar Periradicular Injection: a Non Irradiating Infiltration Technique

Low Back Pain | Sciatica | Chronic Low Back Pain | Pain, Chronic | Disc, Herniated | Foraminal Hernia | Lumbar Foraminal Stenosis | Injection Site Infiltration

Belgium
Bioverativ, a Sanofi company

Completed

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (XTEND-1)

Factor VIII Deficiency

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
Clinical Hospital Centre Zagreb
European Society of Hypertension

Unknown

Blood Pressure Control in ESH Excellence Centres (BP-CON)

White Coat Hypertension | Blood Pressure | Lifestyle Risk Reduction

Israel, Greece, Belgium, Germany, Armenia, Austria, Bulgaria, Croatia, Czechia, Estonia, Italy, Lebanon, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Spain, Sweden, Ukraine, United Kingdom
Medtronic BRC

Completed

Reveal® XT Performance Trial (XPECT)

Atrial Fibrillation | Risk of Cardiac Arrhythmias

Netherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
PedNet Haemophilia Research Foundation
Lund University Hospital

Recruiting

The European Paediatric Network for Haemophilia Management ( PedNet Registry) (PedNet)

Factor IX Deficiency | Factor VIII Deficiency

Norway, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

Hemophilia A | Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

United States, Netherlands, Belgium, France, Germany, South Africa, Spain, Canada, United Kingdom, Poland
Sanofi
Bristol-Myers Squibb

Completed

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Argentina, Denmark, Finland, Hungary, Norway, United... and more
Sanofi
Bristol-Myers Squibb

Terminated

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Russian Federation, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Denmark, Finland, H... and more
Amsterdam UMC

Recruiting

Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma (PREFER)

Barrett Esophagus | Submucosal Esophageal Adenocarcinoma | High-risk Mucosal Esophageal Adenocarcinoma

Netherlands, Belgium, Australia, United Kingdom, Germany, Switzerland
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus

Barrett Esophagus | Adenocarcinoma Esophagus | Submucosal Esophageal Adenocarcinoma | High-risk Mucosal Esophageal Adenocarcinoma

France, United Kingdom, Belgium, Germany, Switzerland, Australia, Netherlands
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)

United States, Belgium, Canada, Italy, Spain, United Kingdom
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
European Organisation for Research and Treatment...

Active, not recruiting

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION)

Malignant Neoplasm of Stomach | Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Epidermal Growth Factor Receptor (EGFR) Protein Overexpression

Spain, Korea, Republic of, Singapore, Switzerland, Germany, United Kingdom, Italy, France, Estonia, Belgium, Netherlands, Norway, Portugal
Boston Scientific Corporation

Completed

Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION)

Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke

Ireland, Spain, Germany, Netherlands, France, United Kingdom, Italy, Russian Federation, Portugal, Belgium, Poland, Saudi Arabia, United Arab Emirates
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Italy, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Finland and more
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
ECRI bv
University of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaborators

Completed

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT)

Coronary Artery Disease | PCI | High Bleeding Risk

Netherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
Ablynx, a Sanofi company

Completed

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

Unstable Angina | Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Stable Angina (Associated With High Risk PCI)

Poland, Belgium, Germany, Israel, Austria, Switzerland, Czechia
European Organisation for Research and Treatment...
Hoffmann-La Roche; UNICANCER; Janssen Diagnostics, LLC; SUCCESS

Completed

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (TREAT-CTC)

Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Circulating Tumor Cells

France, Germany, Belgium, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) (CRYSTAL)

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Sweden, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Austria, Belgium, Finland, Netherlands, Slovakia, Greece, Ta... and more
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

High-Risk Neuroblastoma | Patient With Insufficient Response Chemoimmunotherapy

France, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
Amgen

Terminated

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

High-risk Diffuse Large B-cell Lymphoma

United States, Italy, Belgium, Switzerland, Australia, France, Greece
Janssen Research & Development, LLC

Completed

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

High-risk Smoldering Multiple Myeloma

United States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
AstraZeneca

Completed

Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention (PANDORA)

Peripheral Arterial Disease (PAD) | Moderate Risk for Cardiovascular Disease (CVD)

France, Netherlands, Switzerland, Greece, Belgium, Italy
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Novo Nordisk A/S

Recruiting

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Inflammation | Chronic Kidney Disease | Cardiovascular Risk

Korea, Republic of, Italy, United States, Spain, China, Taiwan, Mexico, Netherlands, Latvia, Malaysia, Thailand, Hungary, Australia, Poland, South Africa, India, Canada, Portugal, Romania, United Kingdom, Bulgaria, Germany, Brazil, Sw... and more
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland

Clinical Trials on Risk Factors in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations